Search Results

Full-year (Aug 2017) and Share performance against CEO & Melbourne, Australia half-year (Feb 2018) results strategy, outlook, organisational Managing identity, generation/age, socio-economic Details of the directors, including their (includes webcast and activities and milestones Director status, religiousMale 70 beliefs,% professionalMale and XX% Male 44% qualifications and experience, together teleconference with questions educationalFemale background 30% as well asFemale global XX% Female 56% with details of their length of service, can and answers) and cultural experiences.

The myelin sheath, or the protective covering of the nerves, is damaged, which In October 2018, an expanded age indication for AFLURIA® may result in numbness or tingling, muscle weakness, fatigue QUADRIVALENT (influenza vaccine) for use in people six and other symptoms which worsen over time.

Translational Medicine was opened in December 2018.

pending test results after 2018), CSL Plasma donors related their Find out more at Find out more at a donation is made.

Vita means life. It's also where CSL shares news and inspiring stories, posted every business day.

The Phase 3 trial, which enrolled its first patient in March of 2018, is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) to reduce the risk of cardiovascular death, myocardial infarction (MI) also known as a heart attack, and stroke in acute myocardial infarction (AMI) patients.

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018

Hizentra was first approved by the U.S. FDA in March 2010 for the treatment of patients with PI and was approved in March 2018 for the treatment of adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.

For the purposes of the Australian Modern Slavery Act 2018 (Cth), this Statement is prepared by and for CSL Limited (ABN 99 051 588 348) and also for the reporting entities CSL Behring (Australia) Pty Ltd (ABN 48 160 734 761) and Seqirus (Australia) Pty Ltd (ABN 66 120 398 067).

Hizentra was first approved by the U.S. FDA in March 2010 for the treatment of patients with PI and was approved in March 2018 for the treatment of adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.